ACE inhibitors, ARBs may slow percent emphysema progression

ACE inhibitors, ARBs may slow percent emphysema progression

(HealthDay)—Use of angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) is associated with slowed progression of percent emphysema on chest computed tomography (CT), according to a study published online Feb. 16 in the Annals of the American Thoracic Society.

Megha A. Parikh, from Columbia University in New York City, and colleagues examined whether ACE inhibitor and ARB dose correlated with the progression of percent on CT in participants of the Multi-Ethnic Study of Atherosclerosis. Data were included for 4,472 participants

The researchers found that 12 and 6 percent of participants used an ACE inhibitor and an ARB, respectively, at baseline. The median percent emphysema was 3.0 at baseline, and over a median of 9.3 years the rate of progression was 0.64 percent. There was an independent correlation for higher doses of ACE inhibitor or ARB with a slower change in percent emphysema (P = 0.03). The predicted mean increase in percent emphysema was 0.66 percent over 10 years in those who did not take ARBs or ACE inhibitors, compared with 0.06 percent among those who used maximum doses of ARBs or ACE inhibitors (P = 0.01). The greatest magnitude of findings was seen among former smokers (P < 0.001).

"Randomized clinical trials of ACE and ARB agents are warranted for the prevention and treatment of emphysema," the authors write.

Two authors disclosed financial ties to the biopharmaceutical industry.


Explore further

Greater emphysema-like lung on CT linked to mortality

More information: Abstract
Full Text (subscription or payment may be required)

Copyright © 2017 HealthDay. All rights reserved.

Citation: ACE inhibitors, ARBs may slow percent emphysema progression (2017, March 17) retrieved 25 July 2021 from https://medicalxpress.com/news/2017-03-ace-inhibitors-arbs-percent-emphysema.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
1 shares

Feedback to editors

User comments